Esther Martinborough
Net worth: 180 650 $ as of 2026-07-30
Net worth: 180 650 $ as of 2026-07-30
Esther Martinborough is currently an Independent Director at Codexis, Inc. since 2021 and a Director at San Diego Squared since 2021.
Former positions include Chief Scientific Officer at Escient Pharmaceuticals, Inc. from 2023 to 2024 and Executive Director-Research at Receptos LLC from 2015 to 2018.
Education includes a doctorate from the Swiss Federal Institute of Technology and graduate studies at the University of California.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CODEXIS, INC. 0.12% | 2026-06-16 | 129,036 ( 0.12% ) | 180 650 $ | 2026-07-30 |
| Companies | Position | Start |
|---|---|---|
| CODEXIS, INC. | Director/Board Member | 2021-02-01 |
| Companies | Position | End |
|---|---|---|
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a drug discovery and development company | Chief Tech/Sci/R&D Officer | 2024-04-30 |
| RECEPTOS INC | Director/Board Member | 2014-12-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Codexis, Inc.
Codexis, Inc. Chemicals: SpecialtyProcess Industries Develops biocatalytic chemical processes | Process Industries |
Receptos LLC
Receptos LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapeutics in immune disease | Health Technology |
Swiss Federal Institute of Technology
Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California
University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a drug discovery and development company | Health Technology |
Select your edition
All financial news and data tailored to specific country editions